(Date:11/24/2009)....24/PRNewswire/--BlueMarbleEnergyCorp.announcedtod...rity(OPDA)wererecentlyawarded$2millionbyWashington...naprivate/publicpartnershiptoconstructthestate,sfi...WA. ,, "Thisinvestmentwillsignificantlyspeedthe...toLincolnCounty,"saidBlueMarbleEnergyCEOKellyOgilv...
(Date:11/24/2009)...v.24,2009/PRNewswire-FirstCall/--ArenaPharmaceutic...anyisscheduledtopresentatthePiperJaffray21stAnnual...ternTime(8:30a.m.PacificTime)attheNewYorkPalaceHot...fExecutiveOfficer,isscheduledtoprovideanoverviewof...veryprograms. ,, Aliveaudiowebcastofthepresenta...
(Date:11/24/2009)....24/PRNewswire-FirstCall/--CellTherapeutics,Inc.(C...stAnnualPiperJaffrayHealthCareConference.Theconfer...otel. ,, CTIwillpresentonTuesday,December1at11:...castofCTI,spresentationwillbeavailableat www.cellt...afterwards. , ,PiperJaffrayHealthCareConference,N...
(Date:11/23/2009)...AGE,Nev.,Nov.23/PRNewswire-FirstCall/--PDLBioPharm...hasestablishedNovember27,2009astheex-dividenddatef...tingfromthesecuritizationtransactioncompletedonNov...toallstockholdersofrecordontherecorddate,December1...edividendat$1.67pershareofcommonstockforpurposesof...
Breaking Biology Technology:Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2PDL BioPharma Announces Ex-Dividend Date of November 27 for Special Dividend 2...l 25 CV Therapeutics,Inc. (Nasdaq: CVTX ) today ...nded March 31, 2008., For the quarter ended March...9 million, or $0.53 per share. This compares to a ... the prior quarter ended December 31, 2007,and $55...er in 2007., For the quarter ended March 31, 2008...
...ntists and Collaborators Publish Study in Science,...bH, the,leading developer of RAFT intervention the...per in Science demonstrating a potential novel str...and other diseases by targeting,discrete sub-compa...nducted,by JADO scientists together with several a...
...lif., April 24 ,Exelixis, Inc. (Nasdaq: EXEL ) an...t and chief executive officer of Exelixis, will pr...ugged Conference at 3:40 p.m. ET/12:40,p.m. PT on ...s updates to,the company,s development pipeline an...ebcast and may be accessed in the Event,Calendar p...
Other Biology Technology:CV Therapeutics Reports 2008 First Quarter Financial Results 2CV Therapeutics Reports 2008 First Quarter Financial Results 3CV Therapeutics Reports 2008 First Quarter Financial Results 4CV Therapeutics Reports 2008 First Quarter Financial Results 5Novel Approach to Treat Alzheimer's and Other Diseases Offered by Targeting Cell Membrane RAFTS 2Novel Approach to Treat Alzheimer's and Other Diseases Offered by Targeting Cell Membrane RAFTS 3Novel Approach to Treat Alzheimer's and Other Diseases Offered by Targeting Cell Membrane RAFTS 4Rabbit Anti-NMDAR1 C2' Polyclonal Antibody, Unconjugated from Abcam
Rabbit Anti-Coronin / CORO1C Polyclonal Antibody, Unconjugated from IMGENEX
Rabbit Anti-Human Retinoic Acid-Induced 3 (RAI3 / RAIG1) Polyclonal Antibody, Unconjugated from IMGENEX
GIBCO Sf-900 Medium (1.3X) liquid from Invitrogen
Biology Products: